OptiBiotix Health (LSE:OPTI) has secured its first significant order from a prominent European weight-management company for its SlimBiome® and WellBiome® formulations—a key milestone in the firm’s strategy to expand its private-label offering. The deal reflects rising market demand for natural, non-GLP1 alternatives in the weight-management sector, which is expected to see strong growth over the coming years. OptiBiotix’s partnerships with global names such as Hydroxycut and LightLife further enhance its industry profile and could help drive stronger sales momentum and long-term value creation.
More about OptiBiotix Health
OptiBiotix Health plc is a life sciences company developing microbiome-focused solutions aimed at improving health and preventing disease. Its portfolio includes SlimBiome®, WellBiome®, SweetBiotix®, and a range of microbiome modulators. The company also maintains strategic interests in related sectors through its holdings in SkinBioTherapeutics PLC and ProBiotix Health plc, expanding its reach across skincare, probiotics, and metabolic health technologies.
Leave a Reply